Electrolyte and Blood Pressure最新文献_第2页

Fatal Hypermagnesemia in Patients Taking Magnesium Hydroxide. 服用氢氧化镁的患者出现致命的高镁血症。

Electrolyte and Blood Pressure Pub Date : 2023-12-01 Epub Date: 2023-12-18 DOI: 10.5049/EBP.2023.21.2.66

Da Hye Jou, Su In Kim, In Hong Choi, Su Hyun Song, Tae Ryom Oh, Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, Soo Wan Kim, Eun Hui Bae, Seong Kwon Ma

{"title":"Fatal Hypermagnesemia in Patients Taking Magnesium Hydroxide.","authors":"Da Hye Jou, Su In Kim, In Hong Choi, Su Hyun Song, Tae Ryom Oh, Sang Heon Suh, Hong Sang Choi, Chang Seong Kim, Soo Wan Kim, Eun Hui Bae, Seong Kwon Ma","doi":"10.5049/EBP.2023.21.2.66","DOIUrl":"10.5049/EBP.2023.21.2.66","url":null,"abstract":"Hypermagnesemia is a rare but potentially fatal electrolyte disorder often overlooked because of its unfamiliarity. Magnesium is regulated through a balance of bone, intestinal absorption, and renal excretion. Hypermagnesemia typically arises from excessive magnesium intake or reduced renal excretion; however, it also occurs in patients with normal kidney function. Herein, we report two cases of hypermagnesemia in patients taking magnesium hydroxide for constipation. The first case involved an 82-year-old woman with end-stage renal disease who developed metabolic encephalopathy due to hypermagnesemia, after taking 3,000 mg of magnesium hydroxide daily for constipation. Her magnesium level was 9.9 mg/dL. Her treatment involved discontinuing magnesium hydroxide and continuing hemodialysis, which led to her recovery. In the second case, a 50-year-old woman with a history of cerebral hemorrhage and mental retardation developed hypermagnesemia despite having normal renal function. She was also taking magnesium hydroxide for constipation, and her magnesium level was 11.0 mg/dL. She experienced cardiac arrest while preparing for continuous renal replacement therapy (CRRT). After achieving return of spontaneous circulation, CRRT was initiated, and her magnesium level showed a decreasing trend. However, vital signs and lactate levels did not recover, leading to death. These cases highlight the importance of prompt diagnosis and intervention for hypermagnesemia and the need to regularly monitor magnesium levels in individuals receiving magnesium-containing preparations, especially those with impaired kidney function.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"21 2","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Efficacy of Single-pill Combination of Olmesartan Medoxomil and Amlodipine Besylate on Office Blood Pressure in Hypertensive Patients who did not Respond to Amlodipine Besylate Monotherapy. 奥美沙坦酯和苯磺酸氨氯地平单药复方制剂对苯磺酸氨氯地平单药治疗无效的高血压患者办公室血压的疗效。

Electrolyte and Blood Pressure Pub Date : 2023-12-01 Epub Date: 2023-12-18 DOI: 10.5049/EBP.2023.21.2.45

Byong-Kyu Kim

{"title":"The Efficacy of Single-pill Combination of Olmesartan Medoxomil and Amlodipine Besylate on Office Blood Pressure in Hypertensive Patients who did not Respond to Amlodipine Besylate Monotherapy.","authors":"Byong-Kyu Kim","doi":"10.5049/EBP.2023.21.2.45","DOIUrl":"10.5049/EBP.2023.21.2.45","url":null,"abstract":"Background: As combination therapy, switching to single-pill combination (SPC) medication after a short period of monotherapy is helpful because reducing pill numbers can improve patients' adherence to medications. This study was aimed to assess the effect of the single-pill combination (SPC) of olmesartan medoxomil 20 mg and amlodipine besylate 5mg (OLM 20 mg/AML 5 mg) on blood pressure (BP) reduction in hypertensive patients who did not respond to amlodipine besylate 5 mg (AML 5 mg) monotherapy for 4 weeks.Methods: This study was a prospective, open-label, multi-center, non-comparative study. Patients whose BP was not got the target BP (≥140 mmHg and if diabetic patients ≥130 mmHg) after 4 weeks treatment with AML 5 mg, were enrolled. AML 5 mg was switched to the SPC (OLM 20 mg/AML 5 mg) treatment for 8 weeks. The primary effectiveness endpoint was the reduction of seated systolic blood pressure (SeSBP) after SPC (OLM 20 mg/AML 5 mg) treatment for 8 weeks. The changes of brachial-ankle pulse wave velocity (baPWV), central BP (CBP), and augmentation index (AIx@75) were evaluated also.Results: Forty-seven patients were enrolled (mean age = 52±9 years, 36 men). After the SPC treatment for 8 weeks, SeSBP was reduced from 153±9 mmHg to 131±18 mmHg and seated diastolic BP (SeDBP) from 95±8 mmHg to 81±11 mmHg (p<0.001 and p<0.001, respectively). The reduction of SeSBP/SeDBP were 22 mmHg and 14 mmHg, respectively. The target goal BP achievement rate was 74.5%, and baPWV, CBP, and AIx@75 were improved.Conclusion: SPC (OLM 20 mg/AML 5 mg) treatment for 8 weeks was effective in reducing BP, achieving target BP goal, and also improving arterial stiffness in uncontrolled hypertensive patients with AML 5 mg monotherapy.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"21 2","pages":"45-52"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osmotic Demyelination Syndrome in a High-Risk Patient Despite Cautious Correction of Hyponatremia. 一名高危患者在谨慎纠正低钠血症后仍出现渗透性脱髓鞘综合征

Electrolyte and Blood Pressure Pub Date : 2023-12-01 Epub Date: 2023-12-18 DOI: 10.5049/EBP.2023.21.2.61

Cheolgu Hwang

{"title":"Osmotic Demyelination Syndrome in a High-Risk Patient Despite Cautious Correction of Hyponatremia.","authors":"Cheolgu Hwang","doi":"10.5049/EBP.2023.21.2.61","DOIUrl":"10.5049/EBP.2023.21.2.61","url":null,"abstract":"Hyponatremia is a common electrolyte disorder requiring careful management to prevent severe complications. Osmotic demyelination syndrome (ODS) is a serious neurological disorder that can develop from rapid correction of hyponatremia. Herein, is a description of the case of a 61-year-old man with multiple risk factors, including alcoholism, hypokalemia, malnutrition, and alcoholic liver cirrhosis, who developed ODS despite adherence to the recommended correction rate for hyponatremia. The patient presented to the emergency department with generalized weakness, gait disturbance, and decreased muscle strength. Initial laboratory investigations revealed severe hyponatremia, hypokalemia, and dehydration. The patient was treated with cautious correction of the hyponatremia below 8 mmol/L per day. However, on the seventh hospital day, he developed tremors, rigidity, and decreased consciousness and was diagnosed with osmotic demyelination syndrome. Despite receiving general supportive care, desmopressin, and dextrose 5% in water to reduce the serum sodium levels, the patient did not show significant improvement and was transferred to a nursing home for long-term conservative care on day 35 of hospitalization. This case report highlights the challenges associated with the diagnosis and management of osmotic demyelination syndrome and the importance of identifying patients at high risk of developing this neurological disorder.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"21 2","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudo-Gitelman Syndrome Presenting with Hypokalemic Metabolic Alkalosis and Hypocalciuria. 出现低钾代谢性碱中毒和低钙尿的假性吉特曼综合征。

Electrolyte and Blood Pressure Pub Date : 2023-12-01 Epub Date: 2023-12-18 DOI: 10.5049/EBP.2023.21.2.72

Seung Heon Lee, Sukyung Lee, Hyunsung Kim, Gheun-Ho Kim

{"title":"Pseudo-Gitelman Syndrome Presenting with Hypokalemic Metabolic Alkalosis and Hypocalciuria.","authors":"Seung Heon Lee, Sukyung Lee, Hyunsung Kim, Gheun-Ho Kim","doi":"10.5049/EBP.2023.21.2.72","DOIUrl":"10.5049/EBP.2023.21.2.72","url":null,"abstract":"Pseudo-Bartter syndrome is a well-known differential diagnosis that needs to be excluded in cases of normotensive hypokalemic metabolic alkalosis. Pseudo-Bartter syndrome and pseudo-Gitelman syndrome are often collectively referred to as pseudo-Bartter/Gitelman syndrome; however, pseudo-Gitelman syndrome should be considered as a separate entity because Gitelman syndrome is characterized by hypocalciuria and hypomagnesemia, while Bartter syndrome is usually associated with hypercalciuria. Herein, we report the cases of two young adult female patients who presented with severe hypokalemic metabolic alkalosis, hypocalciuria, and hypomagnesemia. Diuretic or laxative abuse and self-induced vomiting were absent, and a chloride deficit and remarkable bicarbonaturia were observed. Initial sequencing studies for SLC12A3, CLCKNB, and KCNJ10 revealed no mutations, and whole-exome sequencing revealed no pathogenic variants. The metabolic alkalosis was saline-responsive in one case, and steroid therapy was necessary in the other to relieve chronic tubulointerstitial nephritis, which was diagnosed with kidney biopsy. A new category of pseudo-Gitelman syndrome should be defined, and various etiologies should be investigated.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"21 2","pages":"72-76"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Korean Society of Nephrology 2022 Recommendations on Controversial Issues in Diagnosis and Management of Hyponatremia. 韩国肾脏病学会2022年关于低钠血症诊断和管理争议问题的建议。

Electrolyte and Blood Pressure Pub Date : 2022-06-01 Epub Date: 2022-06-30 DOI: 10.5049/EBP.2022.20.1.21

Yeonhee Lee, Kyung Don Yoo, Seon Ha Baek, Yang Gyun Kim, Hyo Jin Kim, Ji Young Ryu, Jin Hyuk Paek, Sang Heon Suh, Se Won Oh, Jeonghwan Lee, Jong Hyun Jhee, Jin-Soon Suh, Eun Mi Yang, Young Ho Park, Yae Lim Kim, Miyoung Choi, Kook-Hwan Oh, Sejoong Kim

{"title":"Korean Society of Nephrology 2022 Recommendations on Controversial Issues in Diagnosis and Management of Hyponatremia.","authors":"Yeonhee Lee, Kyung Don Yoo, Seon Ha Baek, Yang Gyun Kim, Hyo Jin Kim, Ji Young Ryu, Jin Hyuk Paek, Sang Heon Suh, Se Won Oh, Jeonghwan Lee, Jong Hyun Jhee, Jin-Soon Suh, Eun Mi Yang, Young Ho Park, Yae Lim Kim, Miyoung Choi, Kook-Hwan Oh, Sejoong Kim","doi":"10.5049/EBP.2022.20.1.21","DOIUrl":"https://doi.org/10.5049/EBP.2022.20.1.21","url":null,"abstract":"The Korean Society for Electrolyte and Blood Pressure Research, in collaboration with the Korean Society of Nephrology, has published a clinical practice guideline (CPG) document for hyponatremia treatment. The document is based on an extensive evidence-based review of the diagnosis, evaluation, and treatment of hyponatremia with the multidisciplinary participation of representative experts in hyponatremia with methodologist support for guideline development. This CPG consists of 12 recommendations (two for diagnosis, eight for treatment, and two for special situations) based on eight detailed topics and nine key questions. Each recommendation begins with statements graded by the strength of the recommendations and the quality of the evidence. Each statement is followed by rationale supporting the recommendations. The committee issued conditional recommendations in favor of rapid intermittent bolus administration of hypertonic saline in severe hyponatremia, the use of vasopressin receptor antagonists in heart failure with hypervolemic hyponatremia, and syndrome of inappropriate antidiuresis with moderate to severe hyponatremia, the individualization of desmopressin use, and strong recommendation on the administration of isotonic fluids as maintenance fluid therapy in hospitalized pediatric patients. We hope that this CPG will provide useful recommendations in practice, with the aim of providing clinical support for shared decision-making to improve patient outcomes.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"20 1","pages":"21-38"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/ae/ebp-20-21.PMC9685326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40711516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance. 多囊肾病治疗中的实际问题:血压和水分平衡。

Electrolyte and Blood Pressure Pub Date : 2022-06-01 Epub Date: 2022-06-30 DOI: 10.5049/EBP.2022.20.1.10

Hayne Cho Park, Yun Kyu Oh

{"title":"Practical Issues in the Management of Polycystic Kidney Disease: Blood Pressure and Water Balance.","authors":"Hayne Cho Park, Yun Kyu Oh","doi":"10.5049/EBP.2022.20.1.10","DOIUrl":"https://doi.org/10.5049/EBP.2022.20.1.10","url":null,"abstract":"Autosomal dominant polycystic kidney disease is the most common hereditary renal disease affecting more than 13 million people worldwide. Renal function deteriorates as the cysts in both kidneys increase in number and size, which eventually results in end-stage kidney failure. Until recently, conservative management for chronic kidney disease such as blood pressure control, low sodium diet, adequate water intake, and weight control were known for the only treatment of polycystic kidney disease. However, the introduction of disease-modifying drug has led to the new paradigm shift in the management of polycystic kidney disease. Tolvaptan, the vasopressin V2 receptor antagonist, has been introduced to the patients with large kidneys since it can inhibit cyclic adenosine monophosphate, attenuates cyst growth, and delays renal failure. This article reviews the two important practical issues in the management of polycystic kidney disease: blood pressure and water balance. Firstly, the article will review the pathogenesis of high blood pressure in polycystic kidney disease and will demonstrate the current up-to-date management plan for blood pressure control. Secondly, this article will explain the mechanism of Tolvaptan on the treatment of polycystic kidney disease and its possible adverse effect on water and sodium balance.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"20 1","pages":"10-16"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/91/ebp-20-10.PMC9685325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40711514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potassium Channel Syndrome Caused by Nicorandil in Chronic Kidney Disease: A Case Report and Literature Review. 尼可地尔致慢性肾病钾通道综合征1例并文献复习。

Electrolyte and Blood Pressure Pub Date : 2022-06-01 Epub Date: 2022-06-30 DOI: 10.5049/EBP.2022.20.1.17

Ji-Eun Kim, Seun Deuk Hwang, Seoung Woo Lee, Joon Ho Song, Kipyo Kim

{"title":"Potassium Channel Syndrome Caused by Nicorandil in Chronic Kidney Disease: A Case Report and Literature Review.","authors":"Ji-Eun Kim, Seun Deuk Hwang, Seoung Woo Lee, Joon Ho Song, Kipyo Kim","doi":"10.5049/EBP.2022.20.1.17","DOIUrl":"https://doi.org/10.5049/EBP.2022.20.1.17","url":null,"abstract":"Nicorandil is an anti-anginal drug that is commonly used in the treatment of ischemic heart disease. Nicorandil acts as a nitrate donor and ATP-sensitive potassium channel agonist, inducing coronary artery vasodilation. Potassium efflux through ATP-sensitive potassium channels activated by nicorandil can cause refractory hyperkalemia, particularly in patients with chronic kidney disease (CKD). Here, we report the case of an 85-year-old man who presented with severe refractory hyperkalemia, despite proper medical management. His serum potassium level increased from 4.96 to 7.21 mEq/L 7 days after restarting nicorandil. Hyperkalemia resolved shortly after discontinuation of nicorandil, which was presumed to be the offending drug. Previously, a few cases reported nicorandil-induced hyperkalemia called potassium channel syndrome in patients with CKD, and hyperkalemia can be reversed by ceasing nicorandil or using sulfonyl urea drugs. Given that CKD patients may have several contributing factors to this adverse event, clinicians should be aware of the risk of nicorandil-induced hyperkalemia, and medication review and drug discontinuation should be considered.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"20 1","pages":"17-20"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/76/ebp-20-17.PMC9685324.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40711515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin Sodium and Blood Pressure Regulation. 皮肤钠和血压调节。

Electrolyte and Blood Pressure Pub Date : 2022-06-01 Epub Date: 2022-06-30 DOI: 10.5049/EBP.2022.20.1.1

Jong Hyun Jhee, Hyeong Cheon Park, Hoon Young Choi

{"title":"Skin Sodium and Blood Pressure Regulation.","authors":"Jong Hyun Jhee, Hyeong Cheon Park, Hoon Young Choi","doi":"10.5049/EBP.2022.20.1.1","DOIUrl":"https://doi.org/10.5049/EBP.2022.20.1.1","url":null,"abstract":"Hypertension is a major public health concern due to its high prevalence and increased risk of cardiovascular disease and mortality. Complex traits resulting from both genetic and environmental factors affect the development of hypertension. Among environmental factors, a high salt diet is an important cause for hypertension. Humans show a heterogeneous blood pressure (BP) response to sodium intake. Although the precise mechanisms for the association between salt sensitivity and hypertension have not been fully elucidated, renal sodium handling has been considered to play a pivotal role. However, this conventional view has recently been challenged in that a third compartment, namely, skin may have a role in the regulation of sodium homeostasis. Skin is comprised of a significant portion of interstitium, which is a major extracellular fluid compartment, and its complex capillary network regulates body temperature and skin perfusion. Growing evidence indicates that local regulatory action of cutaneous blood flow as well as salt and water metabolism is associated with systemic BP control. Previous experimental studies have shown that dietary salt loading resulted in nonosmotic sodium accumulation via glycosaminoglycans and lymphatics embedded in the skin that were mediated by several endogenous factors and attenuated an increase in BP. Studies in humans have also suggested that the skin serves as a buffer system for sodium storage and that skin sodium contributes to salt sensitivity and hypertension. Thus, skin sodium storage provides the possibility of being an additional buffering system in response to salt loading and concomitant BP changes in humans.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"20 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/40/ebp-20-1.PMC9685327.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40711517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Adipsic Hypernatremia after Clipping of a Ruptured Aneurysm in the Anterior Communicating Artery: A Case Report. 前交通动脉破裂动脉瘤夹闭后的高钠血症1例。

Electrolyte and Blood Pressure Pub Date : 2021-12-01 Epub Date: 2021-12-23 DOI: 10.5049/EBP.2021.19.2.56

Won Ki Kim, Taeho Lee, Ae Jin Kim, Han Ro, Jae Hyun Chang, Hyun Hee Lee, Wookyung Chung, Ji Yong Jung

{"title":"Adipsic Hypernatremia after Clipping of a Ruptured Aneurysm in the Anterior Communicating Artery: A Case Report.","authors":"Won Ki Kim, Taeho Lee, Ae Jin Kim, Han Ro, Jae Hyun Chang, Hyun Hee Lee, Wookyung Chung, Ji Yong Jung","doi":"10.5049/EBP.2021.19.2.56","DOIUrl":"https://doi.org/10.5049/EBP.2021.19.2.56","url":null,"abstract":"Adipsia is a rare disorder that occurs due to damage to the osmoreceptor and not feeling thirst despite hyperosmolality. Adipsic hypernatremia can occur when there is damage to the anterior communicating artery that supplies blood to osmoreceptors, and the level of arginine vasopressin secretion varies widely. A 37-year-old woman, suffering from severe headache, was consulted to the nephrology department for hypernatremia and polyuria after clipping of a ruptured aneurysm in the anterior communicating artery. Despite her hypernatremic hyperosmolar state, she denied thirst and did not drink spontaneously. She was diagnosed adipsic hypernatremia by evaluating the osmoregulatory and baroregulatory function tests. Because adipsic hypernatremia is caused by not enough drinking water even for hyperosmolality due to the lack of thirst stimulus, the strategies of treatment are that setting the target body weight when serum osmolality is normal and have the patient drink water until patient reach the target body weight. Adipsic hypernatremia should be considered to be a rare complication of subarachnoid hemorrhage associated with an anterior communicating artery aneurysm.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"19 2","pages":"56-60"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/18/ebp-19-56.PMC8715226.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39800584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Understanding of Pressure Natriuresis. 目前对压力性尿钠的认识。

Electrolyte and Blood Pressure Pub Date : 2021-12-01 Epub Date: 2021-12-23 DOI: 10.5049/EBP.2021.19.2.38

Eun Ji Baek, Sejoong Kim

{"title":"Current Understanding of Pressure Natriuresis.","authors":"Eun Ji Baek, Sejoong Kim","doi":"10.5049/EBP.2021.19.2.38","DOIUrl":"https://doi.org/10.5049/EBP.2021.19.2.38","url":null,"abstract":"Pressure natriuresis refers to the concept that increased renal perfusion pressure leads to a decrease in tubular reabsorption of sodium and an increased sodium excretion. The set point of blood pressure is the point at which pressure natriuresis and extracellular fluid volume are in equilibrium. The term \"abnormal pressure natriuresis\" usually refers to the expected abnormal effect of a certain level of blood pressure on sodium excretion. Factors that cause abnormal pressure natriuresis are known. Sympathetic nerve system, genetic factors, and dietary factors may affect an increase in renal perfusion pressure. An increase in renal perfusion pressure increases renal interstitial hydrostatic pressure (RIHP). Increased RIHP affects tubular reabsorption through alterations in tight junctional permeability to sodium in proximal tubules, redistribution of apical sodium transporters, and/or release of renal autacoids. Renal autocoids such as nitric oxide, prostaglandin E2, kinins, and angiotensin II may also regulate pressure natriuresis by acting directly on renal tubule sodium transport. In addition, inflammation and reactive oxygen species may mediate pressure natriuresis. Recently, the use of new drugs associated with pressure natriuretic mechanisms, such as angiotensin receptor neprilysin inhibitor and sodium glucose co-transporter 2 inhibitors, has been consistently demonstrated to reduce mortality and hypertension-related complications. Therefore, the understanding of pressure natriuresis is gaining attention as an antihypertensive strategy. In this review, we provide a basic overview of pressure natriuresis to the target audience of nephrologists.","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"19 2","pages":"38-45"},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/4d/ebp-19-38.PMC8715224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39800581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6